AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19521272
Drug: Expectations of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectations of treatment (baseline expectations)
Trial: 2453619
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy regimen (PVeBV)
Trial: 2453619
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy regimen (PVeB)
Trial: 29871240
Drug: Acoustic resonance
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoustic resonance therapy combined with systemic steroid therapy and conventional drug therapy
Trial: 29871240
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy and conventional drug therapy
Trial: 25433294
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of real-time feedback and JIT CPR training
Trial: 11580734
Drug: Gestational diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestational diabetes mellitus (GDM) treatment with low-caloric diet and insulin when appropriate
Trial: 26682290
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream 3.75% applied once daily until complete clearance or a maximum of 8 weeks
Trial: 26682290
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream 2.5% applied once daily until complete clearance or a maximum of 8 weeks
Trial: 22925000
Drug: Procalcitonin ultrasensitive-guided
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin ultrasensitive-guided antibiotic treatment
Trial: 8987040
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg/kg
Trial: 7818124
Drug: Atracurium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.3 mg/kg
Trial: 23834406
Drug: CD only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD only (nurse administered)
Trial: 19060515
Drug: hylan G‐F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hylan G‐F 20 (Synvisc), 2 ml, three intra-articular injections
Trial: 19060515
Drug: sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium hyaluronate (Hyalgan), 2 ml, five intra-articular injections
Trial: 19060515
Drug: No injections
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injections (controls)
Trial: 9141257
Drug: Aspirin 15
RxNorm normalized name: aspirin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 15 mg/kg
Trial: 6690170
Drug: Oral nalbuphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nalbuphine, 15 mg (N = 39)
Trial: 6690170
Drug: Codeine, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine, 60 mg (N = 42)
Trial: 6690170
Drug: Oral nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nalbuphine (N = 39)
Trial: 19228175
Drug: Both active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both active drugs
Trial: 26350171
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of oral BP treatment for up to 10 years
Trial: 26350171
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of intravenous BP treatment for up to 6 years
Trial: 22252366
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vitamin E in crude soybean oil diet
Trial: 22252366
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg vitamin E in crude soybean oil diet
Trial: 22252366
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vitamin E in acidulated soybean oil soapstock diet
Trial: 9284856
Drug: Troglitazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (200 mg/day)
Trial: 3541426
Drug: ID-1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID-1 group (3 doses of 0.1 ml intradermally at 0, 1 month, and 4 months)
Trial: 3541426
Drug: ID-2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID-2 group (2 doses of 0.2 ml intradermally at 0 and 1 dose of 0.1 ml at 4 months)
Trial: 10958810
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation at 15 mg (RDA)
Trial: 8898643
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg/4 h)
Trial: 8898643
Drug: Somatostatin (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (continuous infusion of 250 micrograms/h after an intravenous injection of 250 micrograms)
Trial: 31303706
Drug: Palonosetron (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (1 mcg/kg, max 75 mcg)
Trial: 31303706
Drug: Ondansetron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.1 mg/kg, max 8 mg)
Trial: 16846342
Drug: beta‐TCP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐TCP + 1.0 mg/mL of recombinant human PDGF‐BB (rhPDGF‐BB)
Trial: 2579938
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy following irradiation
Trial: 28335729
Drug: 5 weeks
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 weeks of training with an oral screen for neuromuscular training focused on orofacial and pharyngeal muscles
Trial: 25774595
Drug: Risk model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk model association with response to therapy, overall and GVHD-specific survival and non-relapse mortality
Trial: 19374150
Drug: Healthy older
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy older adults swallowing various bolus types (5 or 10 mL)
Trial: 17988533
Drug: Oxymatrine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymatrine (600 mg, intravenous drip, once a day for 7 days)
Trial: 17988533
Drug: Traditional equilibrium
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional equilibrium salt treatment (control group)
Trial: 9400460
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (10 ml)
Trial: 138557
Drug: 0.025% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% betamethasone benzoate gel
Trial: 3582724
Drug: 0.1% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% betamethasone valerate cream
Trial: 22669627
Drug: Po-husk (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Po-husk (14 g/day)
Trial: 22669627
Drug: Placebo (microcrystalline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (microcrystalline cellulose 14 g/day)
Trial: 28166613
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs (methotrexate, cyclosporin)
Trial: 16133653
Drug: Combined weight-bearing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined weight-bearing training program (50 min, twice a week)
Trial: 26163609
Drug: Tailored triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored triple therapy with placebo (esomeprazole 20 mg bid, clarithromycin 500 mg bid or metronidazole 400 mg tid if clarithromycin resistance and amoxicillin 1000 mg bid)
Trial: 26163609
Drug: Tailored triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored triple therapy plus pretreatment with probiotic containing yogurt
Trial: 14520776
Drug: Tooth whitening
RxNorm normalized name: CAMPHOR, (-)- 1 g in 24 g TOPICAL PATCH [Tooth Whitening Strip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth whitening gel containing 25% carbamide peroxide
Trial: 14520776
Drug: Tooth whitening
RxNorm normalized name: CAMPHOR, (-)- 1 g in 24 g TOPICAL PATCH [Tooth Whitening Strip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth whitening gel containing 8.7% hydrogen peroxide
Trial: 19820754
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor + Angiotensin receptor blocker (lisinopril 10 mg/day + candesartan 16 mg/day)
Trial: 19820754
Drug: Aldosterone antagonist
RxNorm normalized name: Aldosterone antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone antagonist (eplerenone 25 mg/day)
Trial: 19820754
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (lisinopril 20 mg/day)
Trial: 11077029
Drug: Rifampicin 1200
RxNorm normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 1200 mg/day in two divided doses
Trial: 9217894
Drug: Insulin with
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin with L-NMMA (30 micrograms/kg/min)
Trial: 9217894
Drug: Insulin with
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin with propranolol (0.2 microgram/kg/min)
Trial: 9217894
Drug: L-NMMA (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (30 micrograms/kg/min) alone
Trial: 775954
Drug: Intravenous digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous digoxin
Trial: 27770820
Drug: Contingency Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency Management (CM) intervention with 12 once-weekly sessions and voucher rewards for cannabis-free urinalysis
Trial: 27770820
Drug: Optimised Treatment
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised Treatment as Usual (OTAU) psychoeducational package
Trial: 23905488
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (50 mg daily for 12 weeks)
Trial: 23905488
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (600 mg parenterally for 7 days, followed by 600 mg orally for 12 weeks)
Trial: 23905488
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Transdermal testosterone and Alpha-lipoic acid)
Trial: 21090960
Drug: SADV (coordinated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SADV (coordinated substance abuse and domestic violence treatment program)
Trial: 17029131
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine (single dose)
Trial: 8561324
Drug: IV clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV clonidine treatment
Trial: 30203386
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg for 5 days
Trial: 30203386
Drug: Baloxavir marboxil
RxNorm normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baloxavir marboxil 40 mg with oseltamivir 75 mg for 5 days
Trial: 23244155
Drug: Psychoeducational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational program (eight 90 minute weekly sessions)
Trial: 7008062
Drug: Vehicle infusion
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle infusion (control)
Trial: 2752040
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment (325 mg/d)
Trial: 616222
Drug: lynestrenol 0.5
RxNorm normalized name: lynestrenol 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lynestrenol 0.5 mg
Trial: 616222
Drug: lynestrenol 0.5
RxNorm normalized name: lynestrenol 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lynestrenol 0.5 mg + ethinyl estradiol 0.05 mg
Trial: 616222
Drug: d‐norgestrel 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐norgestrel 0.25 mg + ethinyl estradiol 0.05 mg
Trial: 23030716
Drug: Dutasteride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (0.5 mg/day) for 6 weeks before surgery
Trial: 26093811
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg
Trial: 26093811
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg
Trial: 17190950
Drug: Immediate antiepileptic
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antiepileptic treatment
Trial: 21531706
Drug: Treatment only
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment only in the event of seizure recurrence
Trial: 3545246
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with codeine (300-600 mg with 30-60 mg codeine) and placebo TENS
Trial: 2571492
Drug: Lefetamine administered
RxNorm normalized name: amfetamine
DrugBank: Amphetamine (DB00182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lefetamine administered to opiate addicts with acute withdrawal syndrome
Trial: 10321522
Drug: PUVA-cream therapy
RxNorm normalized name: dimethicone Topical Cream [Mederma Stretch Mark Therapy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA-cream therapy
Trial: 1926059
Drug: Dermatan sulfate
RxNorm normalized name: dermatan sulfate
DrugBank: Dermatan sulfate (DB15880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatan sulfate (DS) 400 mg
Trial: 1926059
Drug: Heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5,000 IU
Trial: 6760652
Drug: Natamycin vaginal
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Natamycin vaginal tablets for 10 days, partners treated with natamycin cream
Trial: 6760652
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream for partners
Trial: 28215166
Drug: Current anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current anti-inflammatory drugs
Trial: 25956843
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (L‐AmB) inhalation
Trial: 25956843
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L‐AmB inhalation)
Trial: 16467677
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin 0.5% (1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery)
Trial: 16467677
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin 0.5% (self-administered 4 times daily for 3 days before surgery and at 7 am on the day of surgery)
Trial: 16467677
Drug: Topical gatifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gatifloxacin 0.3% (1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery)
Trial: 16467677
Drug: Topical gatifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gatifloxacin 0.3% (self-administered 4 times daily for 3 days before surgery and at 7 am on the day of surgery)
Trial: 30887764
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill (OCP)
Trial: 9124829
Drug: Foscarnet (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet (intravenous dosages for 10 days)
Trial: 1425160
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (6-20 IU at bedtime plus oral drugs)
Trial: 6737950
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (12 U hGH/m2 per week)
Trial: 30393077
Drug: Baseline dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline dietary intake assessment using Automated Self‐Administered 24‐Hour Recall; participants reported food intake on 3 nonconsecutive days.
Trial: 29762043
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil 1.6 g/day for 12 weeks
Trial: 24040856
Drug: Ephedrine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (0.02 mg×kg‐1×min‐1)
Trial: 24040856
Drug: Phenylephrine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (0.25 μg×kg‐1×min‐1)
Trial: 18178070
Drug: ITRA‐GSMP capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITRA‐GSMP capsule (50mg itraconazole)
Trial: 17000452
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg pilocarpine (Salagen) four times daily for 12 weeks
Trial: 14525814
Drug: Statistical process
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical process control methods applied to analyze medication errors
Trial: 11038436
Drug: Celgene thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Celgene thalidomide capsules (200 mg) under fasted conditions
Trial: 11038436
Drug: Celgene thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Celgene thalidomide capsules (200 mg) with food
Trial: 11038436
Drug: Serral thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Serral thalidomide tablets (200 mg) under fasted conditions
Trial: 7768585
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium 25 mg
Trial: 21029622
Drug: Drug eluting
RxNorm normalized name: Drug eluting stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug eluting stent
Trial: 998673
Drug: Full-course radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-course radiation therapy
Trial: 16375890
Drug: Delta(9)‐THC 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta(9)‐THC 5 mg orally
Trial: 16375890
Drug: Morphine 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.02 mg/kg intravenously
Trial: 30802419
Drug: Vortioxetine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (10-20 mg/day)
Trial: 22967863
Drug: Oral minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral minocycline and artificial tears
Trial: 12232493
Drug: Control (spa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (spa therapy)
Trial: 17727882
Drug: Desipramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine treatment
Trial: 22985610
Drug: Amiodarone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (600 mg the night before surgery and 400 mg twice daily for 4 to 6 days post-surgery)
Trial: 17985384
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intracoronary adenosine
Trial: 471857
Drug: i.v. domperidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. domperidone (0.35 and 0.7 mg/kg)
Trial: 30795749
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy
Trial: 27803094
Drug: Sbv (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sbv (20 mg/kg/d for 20 days)
Trial: 15101068
Drug: Guided self‐help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided self‐help (self‐help manual with a maximum of 18 short weekly visits)
Trial: 15101068
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBT) (18 weekly 1.5‐h sessions)
Trial: 9677215
Drug: Selegiline (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (alone or in combination with levodopa)
Trial: 27324883
Drug: Balneotherapy (sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy (sulfur bath) combined with home exercise therapy
Trial: 27324883
Drug: Home exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home exercise therapy alone